Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 14/20 | 0.81 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485965 | 0.90 | F2R (1.00) | F2RAKR1C3TACR1RORC | |
| SCHEMBL661199 | 0.89 | F2R (0.74) | F2RAKR1C3TACR1 | |
| SCHEMBL662485 | 0.88 | F2R (0.80) | F2RAKR1C3TACR1EPHX2 | |
| SCHEMBL486059 | 0.88 | F2R (0.73) | F2RAKR1C3TACR1EPHX2RORC | |
| SCHEMBL662187 | 0.87 | F2R (0.64) | F2RAKR1C3TACR1 | |
| SCHEMBL16587865 | 0.86 | F2R (0.70) | F2RAKR1C3TACR1EPHX2RORC | |
| SCHEMBL10242105 | 0.86 | F2R (0.70) | F2RAKR1C3TACR1RORC | |
| SCHEMBL662458 | 0.85 | F2R (0.81) | F2R | |
| SCHEMBL485914 | 0.84 | F2R (0.67) | F2RAKR1C3TACR1EPHX2RORC | |
| SCHEMBL13191823 | 0.84 | F2R (1.00) | F2RAKR1C3TACR1USP2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150183773-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-8987248-B2 | Substituted piperidines as Par-1 antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183773-A1 | Substituted piperidines | VHL, PIR, PIGO | F2R 1243/4885AKR1C3 2255/4885TACR1 683/4885 |
| US-20120046268-A1 | Substituted piperidines as Par-1 Antagonists | F2R, F2RL1, F2RL3 | F2R 1/4885AKR1C3 1889/4885TACR1 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.